Xxcorxxheaxxhcaxx Ptxxlimited Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Xxcorxxheaxxhcaxx Ptxxlimited Pharmaceutical Import Records from India — 2 Products, $200.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxcorxxheaxxhcaxx Ptxxlimited — Pharmaceutical Importer Profile (2026) | 2 Products, $200.0K Trade | TransData Nexus

Xxcorxxheaxxhcaxx Ptxxlimited

Pharmaceutical Importer · Australia · Oncology Focus · $200.0K Total Trade · DGFT Verified

Xxcorxxheaxxhcaxx Ptxxlimited is a pharmaceutical importer based in Australia with a total trade value of $200.0K across 2 products in 2 therapeutic categories. Based on 4 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxcorxxheaxxhcaxx Ptxxlimited sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Xxcorxxheaxxhcaxx Ptxxlimited — Import Portfolio & Supplier Network

Xxcorxxheaxxhcaxx Ptxxlimited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxcorxxheaxxhcaxx Ptxxlimited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$350.0K	7	100.0%

Xxcorxxheaxxhcaxx Ptxxlimited sources from 1 verified Indian supplier across 4 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cisplatin	Oncology	$100.0K	2	0.8%	14
2	Pemetrexed	Advanced Oncology	$100.0K	2	0.3%	16

Xxcorxxheaxxhcaxx Ptxxlimited imports 2 pharmaceutical products across 2 categories into Australia totaling $200.0K.

Xxcorxxheaxxhcaxx Ptxxlimited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxcorxxheaxxhcaxx Ptxxlimited is an Australian pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered in Australia and operates as an independent entity without a publicly known parent company. Its primary role in the Australian pharmaceutical distribution network involves sourcing and importing specific oncology medications to meet domestic demand.

The company's import activities are focused on high-demand oncology drugs, indicating a strategic emphasis on this therapeutic area. By importing these specialized medications, Xxcorxxheaxxhcaxx Ptxxlimited plays a crucial role in ensuring the availability of essential cancer treatments within Australia.

2Distribution Network

Specific details regarding Xxcorxxheaxxhcaxx Ptxxlimited's warehouse locations and logistics capabilities are not publicly disclosed. However, as a pharmaceutical importer, the company is likely to collaborate with established logistics providers to ensure the efficient distribution of imported medications across Australia. This collaboration would typically involve warehousing facilities compliant with Australian regulations and a distribution network capable of delivering products to various healthcare providers, including hospitals, clinics, and pharmacies.

3Industry Role

Xxcorxxheaxxhcaxx Ptxxlimited functions as a pharmaceutical importer within Australia's supply chain. Its role is to source and import finished pharmaceutical formulations, particularly in the oncology sector, to meet the domestic market's needs. By focusing on importing specific oncology medications, the company ensures that these essential treatments are available to Australian patients, thereby supporting the healthcare system's capacity to provide comprehensive cancer care.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxcorxxheaxxhcaxx Ptxxlimited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxcorxxheaxxhcaxx Ptxxlimited's sourcing strategy exhibits a high degree of concentration, with all its imports originating from a single supplier, INTAS Pharmaceuticals Limited. This single-source dependency could pose risks, such as supply chain disruptions due to geopolitical issues, manufacturing problems, or regulatory changes affecting the supplier. The company's reliance on INTAS Pharmaceuticals Limited for all its imported products suggests a strategic choice to maintain consistency and quality in its product offerings. However, this approach also underscores the importance of robust risk management strategies to mitigate potential disruptions.

The shipment data indicates a stable relationship between Xxcorxxheaxxhcaxx Ptxxlimited and INTAS Pharmaceuticals Limited, with seven shipments valued at $350K USD. This consistent trading pattern suggests a reliable and ongoing partnership. Nonetheless, the lack of diversification in sourcing could limit the company's ability to adapt to changes in the global pharmaceutical market.

2Supply Chain Resilience

Xxcorxxheaxxhcaxx Ptxxlimited's supply chain resilience appears limited due to its exclusive reliance on INTAS Pharmaceuticals Limited for all imported products. The absence of backup suppliers means that any disruption at INTAS Pharmaceuticals Limited could significantly impact Xxcorxxheaxxhcaxx Ptxxlimited's ability to meet domestic demand. Additionally, the company's focus on a narrow range of formulations—cisplatin and pemetrexed—further constrains its supply chain flexibility. To enhance resilience, it would be prudent for Xxcorxxheaxxhcaxx Ptxxlimited to consider diversifying its supplier base and expanding its product portfolio.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the regulation of therapeutic goods, including pharmaceuticals, is overseen by the Therapeutic Goods Administration (TGA), a division of the Department of Health and Aged Care. The TGA is responsible for ensuring that therapeutic goods are safe, effective, and of high quality before they can be supplied in Australia. This includes assessing and approving medicines, medical devices, and other therapeutic products for inclusion in the Australian Register of Therapeutic Goods (ARTG). (tga.gov.au)

The primary legislation governing the regulation of therapeutic goods in Australia is the Therapeutic Goods Act 1989. This Act establishes the framework for the regulation of therapeutic goods, including their importation, manufacture, and supply. It outlines the requirements for market authorisation, quality standards, and compliance obligations for sponsors and manufacturers. (business.gov.au)

2Import Licensing & GMP

To import therapeutic goods into Australia, companies must comply with the Therapeutic Goods Act 1989 and associated regulations. This includes obtaining market authorisation from the TGA, which involves demonstrating that the goods meet Australian standards for safety, quality, and efficacy. Importers must ensure that their products are included in the ARTG before they can be legally supplied in Australia. (tga.gov.au)

Xxcorxxheaxxhcaxx Ptxxlimited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxcorxxheaxxhcaxx Ptxxlimited's focus on importing oncology medications, specifically cisplatin and pemetrexed, indicates a strategic alignment with the high demand for cancer treatments in Australia. The company's import activities are driven by the need to ensure a consistent supply of these essential drugs, which are critical in the management of various cancers. By concentrating on these specific formulations, Xxcorxxheaxxhcaxx Ptxxlimited aims to meet the therapeutic needs of Australian patients and healthcare providers.

2Sourcing Profile

Xxcorxxheaxxhcaxx Ptxxlimited's sourcing strategy is centered on importing generic formulations of cisplatin and pemetrexed from INTAS Pharmaceuticals Limited. This approach allows the company to provide cost-effective alternatives to branded medications, making cancer treatments more accessible to the Australian market. The company's focus on these specific formulations suggests a targeted procurement strategy aimed at addressing the therapeutic needs in the oncology sector.

3Market Positioning

Based on its product mix, Xxcorxxheaxxhcaxx Ptxxlimited serves the Australian market segment that includes hospitals, oncology clinics, and specialized pharmacies. By importing essential oncology medications, the company supports the healthcare system's capacity to provide comprehensive cancer care. Its role is crucial in ensuring that these critical treatments are available to patients, thereby contributing to the overall effectiveness of cancer management in Australia.

Seller's Guide — How to Become a Supplier to Xxcorxxheaxxhcaxx Ptxxlimited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Xxcorxxheaxxhcaxx Ptxxlimited by offering alternative sources for cisplatin and pemetrexed. Diversifying the supplier base could enhance supply chain resilience and reduce dependency on a single source. Additionally, introducing new formulations or related oncology medications could address unmet needs in the Australian market, providing a competitive edge for both the importer and the supplier.

2Requirements & Qualifications

Indian exporters seeking to supply Xxcorxxheaxxhcaxx Ptxxlimited and the Australian market must ensure that their products are included in the Australian Register of Therapeutic Goods (ARTG). This requires obtaining market authorisation from the Therapeutic Goods Administration (TGA), demonstrating compliance with Australian standards for safety, quality, and efficacy. Additionally, products must be manufactured in accordance with Good Manufacturing Practice (GMP) standards recognized by the TGA. Proper labeling in accordance with Australian regulations is also essential. (tga.gov.au)

3How to Approach

Frequently Asked Questions — Xxcorxxheaxxhcaxx Ptxxlimited

What products does Xxcorxxheaxxhcaxx Ptxxlimited import from India?

Xxcorxxheaxxhcaxx Ptxxlimited imports 2 pharmaceutical products across 2 categories. Top imports: Cisplatin ($100.0K), Pemetrexed ($100.0K).

Who supplies pharmaceuticals to Xxcorxxheaxxhcaxx Ptxxlimited from India?

Xxcorxxheaxxhcaxx Ptxxlimited sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $350.0K).

What is Xxcorxxheaxxhcaxx Ptxxlimited's total pharmaceutical import value?

Xxcorxxheaxxhcaxx Ptxxlimited's total pharmaceutical import value from India is $200.0K, based on 4 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxcorxxheaxxhcaxx Ptxxlimited focus on?

Xxcorxxheaxxhcaxx Ptxxlimited imports across 2 categories. The largest: Oncology (50.0%), Advanced Oncology (50.0%).

Get Full Xxcorxxheaxxhcaxx Ptxxlimited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Formulation	Value	Ships
Cisplatin acc INJ 100MG/100ML	$100.0K	2
Pemetrexed accord 1000MG 1x1v	$100.0K	2
Azacitidine accord	$100.0K	2
Doxorubicin acc 200MG/100ML	$50.0K	1